R D L Akkerman1, L Haverkamp1, P S N van Rossum2, R van Hillegersberg1, J P Ruurda3. 1. Department of Surgery, University Medical Center Utrecht, The Netherlands. 2. Department of Surgery, University Medical Center Utrecht, The Netherlands; Department of Radiotherapy, University Medical Center Utrecht, The Netherlands. 3. Department of Surgery, University Medical Center Utrecht, The Netherlands. Electronic address: J.P.Ruurda@umcutrecht.nl.
Abstract
BACKGROUND: Gaining insight in long-term health-related quality of life more than 1year after oesophagectomy will assist clinical decision-making and inform patients about the long-term consequences of surgery. METHODS: In this cross-sectional study, all consecutive patients who underwent oesophageal resection with gastric interposition for cancer at a tertiary referral centre between January 2007 and July 2012 were included. European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 and QLQ-OES18 were sent to all patients alive without recurrence more than 1year after surgery. RESULTS: The questionnaires were completed by 92 of 100 patients. Median duration of follow-up after surgery at completing the questionnaire was 36months (range: 12-75). Global quality of life scores were similar to a general population reference group (76±19 versus 78±17; p=0.26). However, patients scored significantly worse compared to the general population reference group on physical-, role-, cognitive- and social functioning (p<0.001). Neoadjuvant therapy and minimally invasive oesophagectomy were associated with significantly better health-related quality of life (HRQL) and symptom scores (p<0.05). CONCLUSION: Global HRQL more than 1year after oesophagectomy with gastric tube reconstruction is comparable to the general Dutch background population, while specific functional and symptom scores are significantly worse. Neoadjuvant therapy and minimally invasive surgery are associated with quality of life benefits in long-term survivors.
BACKGROUND: Gaining insight in long-term health-related quality of life more than 1year after oesophagectomy will assist clinical decision-making and inform patients about the long-term consequences of surgery. METHODS: In this cross-sectional study, all consecutive patients who underwent oesophageal resection with gastric interposition for cancer at a tertiary referral centre between January 2007 and July 2012 were included. European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 and QLQ-OES18 were sent to all patients alive without recurrence more than 1year after surgery. RESULTS: The questionnaires were completed by 92 of 100 patients. Median duration of follow-up after surgery at completing the questionnaire was 36months (range: 12-75). Global quality of life scores were similar to a general population reference group (76±19 versus 78±17; p=0.26). However, patients scored significantly worse compared to the general population reference group on physical-, role-, cognitive- and social functioning (p<0.001). Neoadjuvant therapy and minimally invasive oesophagectomy were associated with significantly better health-related quality of life (HRQL) and symptom scores (p<0.05). CONCLUSION: Global HRQL more than 1year after oesophagectomy with gastric tube reconstruction is comparable to the general Dutch background population, while specific functional and symptom scores are significantly worse. Neoadjuvant therapy and minimally invasive surgery are associated with quality of life benefits in long-term survivors.
Authors: Teus J Weijs; Hanneke W J van Eden; Jelle P Ruurda; Misha D P Luyer; Elles Steenhagen; Grard A P Nieuwenhuijzen; Richard van Hillegersberg Journal: J Thorac Dis Date: 2017-07 Impact factor: 2.895
Authors: Jonna K van Vulpen; Peter D Siersema; Richard van Hillegersberg; Grard A P Nieuwenhuijzen; Ewout A Kouwenhoven; Richard P R Groenendijk; Donald L van der Peet; Eric J Hazebroek; Camiel Rosman; Carlo C G Schippers; Elles Steenhagen; Petra H M Peeters; Anne M May Journal: BMC Cancer Date: 2017-08-18 Impact factor: 4.430
Authors: Hylke J F Brenkman; Juul J W Tegels; Jelle P Ruurda; Misha D P Luyer; Ewout A Kouwenhoven; Werner A Draaisma; Donald L van der Peet; Bas P L Wijnhoven; Jan H M B Stoot; Richard van Hillegersberg Journal: Gastric Cancer Date: 2017-10-24 Impact factor: 7.370
Authors: Nils Heits; Alexander Bernsmeier; Benedikt Reichert; Charlotte Hauser; Alexander Hendricks; Dana Seifert; Florian Richter; Clemens Schafmayer; Mark Ellrichmann; Bodo Schniewind; Jochen Hampe; Thomas Becker; Jan-Hendrik Egberts Journal: J Thorac Dis Date: 2018-01 Impact factor: 2.895